Menveo market to grow on rising meningitis cases and vaccine demand

The Business Research Company says the Menveo vaccine market is set for continued expansion through 2035, driven by rising meningitis prevalence, broader immunization coverage and stronger healthcare infrastructure. North America led the market in 2025, while Asia-Pacific is forecast to grow the fastest.

Why it matters: - Menveo protects against Neisseria meningitidis serogroups A, C, W and Y, which can cause meningitis and bloodstream infections. - The market outlook matters because higher meningitis incidence and broader vaccination programs can lift demand for preventive vaccines across adolescents, young adults and high-risk groups. - The report points to wider implications for public health planning, travel medicine and outbreak prevention.

What happened: - The Business Research Company published a Menveo market report covering market size, trends and a global forecast for 2026-2035. - The report says the Menveo market expanded in the historical period because of broader national immunization schedules, prior meningococcal outbreaks, conjugate vaccine advances, public awareness and large-scale vaccination campaigns. - The company expects growth to continue through the forecast period, supported by vaccine R&D, outbreak prevention efforts, broader adult and adolescent coverage, travel vaccine demand and stronger public health systems. - The report includes a free sample of the market study: Download the sample report. - The full report is available here: View the full market report.

The details: - Menveo is primarily recommended for adolescents, young adults and people at higher risk of meningococcal disease. - The report identifies growing uptake of conjugate vaccines as a major trend because of their stronger protection profile. - Preventive immunization programs are gaining emphasis as health systems try to reduce disease incidence. - Demand is rising for vaccines aimed at adolescents and travelers. - Multivalent vaccine coverage is expanding, adding to market momentum. - Rising meningitis prevalence is a key growth catalyst. - Meningitis can be caused by bacteria, viruses or fungi, and global travel and weakened immune systems can contribute to spread. - In October 2025, the UK Health Security Agency reported 378 confirmed invasive meningococcal disease cases during 2024-25. - Healthcare infrastructure growth is also supporting the market because vaccines are being integrated into clinics, hospitals and public health campaigns. - The report cites UK healthcare spending growth of 5.6% in nominal terms from 2022 to 2023, up from 0.9% in the prior year, based on Office for National Statistics data. - The analysis covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - North America held the largest Menveo market share in 2025. - Asia-Pacific is projected to grow the fastest during the forecast period. - The 2026 report set adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated technology and future-trend analysis.

Between the lines: - The report frames Menveo less as a standalone product story and more as part of a broader shift toward preventive vaccination and stronger outbreak preparedness. - The emphasis on travel vaccines and adolescent coverage suggests demand is being shaped by mobility and routine immunization policy, not just disease outbreaks. - Stronger healthcare infrastructure can widen access, but regional growth will likely depend on how quickly countries expand vaccination programs and funding.

What's next: - The report expects continued market growth through 2035 if governments, providers and vaccine programs keep expanding coverage. - Asia-Pacific’s faster projected growth suggests future demand will increasingly come from emerging and scaling healthcare markets. - The company directs readers to its sales and contact channels for more information, including Saumya Sahay at marketing@tbrc.info and the company’s social media pages LinkedIn and company profile.